Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Gevotroline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.77 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.60 |
| ▸ | APAF1 | O14727 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gevotroline SCHEMBL120422 | 1.00 | SIGMAR1 (0.77) | SIGMAR1ACHEAPAF1 | |
| Gevotroline SCHEMBL31395347 | 1.00 | SIGMAR1 (0.77) | SIGMAR1ACHEAPAF1 | |
| Gevotroline SCHEMBL4684544 | 1.00 | SIGMAR1 (0.77) | SIGMAR1ACHEAPAF1 | |
| Gevotroline SCHEMBL30124880 | 0.99 | SIGMAR1 (0.78) | SIGMAR1ACHE | |
| Gevotroline SCHEMBL29710901 | 0.99 | SIGMAR1 (0.78) | SIGMAR1ACHE | |
| Gevotroline SCHEMBL293396 | 0.99 | SIGMAR1 (0.78) | SIGMAR1ACHE | |
| SCHEMBL10375702 | 0.87 | SIGMAR1 (1.00) | SIGMAR1ACHEAPAF1 | |
| SCHEMBL10375956 | 0.87 | SIGMAR1 (0.63) | SIGMAR1ACHE | |
| SCHEMBL10375595 | 0.84 | SIGMAR1 (0.94) | SIGMAR1APAF1 | |
| Carvotroline SCHEMBL123737 | 0.82 | SIGMAR1 (0.86) | SIGMAR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086538-B1 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING DIMEBON AND DONEPEZIL | MEDIVATION NEUROLOGY INC (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2420235-A1 | Methods and combination therapies for treating alzheimer's disease | Medivation Neurology, Inc. (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20110269777-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA USING ANTIPSYCHOTIC COMBINATION THERAPY | MEDIVATION NEUROLOGY, INC. | 2011-11-03 | — | — | US | disclosed |
| US-20100178277-A1 | METHODS AND COMPOSITIONS FOR STIMULATING CELLS | MEDIVATION NEUROLOGY, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | MEDIVATION NEUROLOGY, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152225-A1 | HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME | MEDIVATION NEUROLOGY, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100099700-A1 | HYDROGENATED PYRIDO (4,3-B) INDOLES FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | MEDIVATION NEUROLOGY, INC. | 2010-04-22 | — | — | US | disclosed |
| EP-2155196-A1 | METHODS AND COMPOSITIONS FOR STIMULATING CELLS | Medivation Neurology, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2086538-A2 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING I.A. DIMEBON AND DOLEPEZIL | Medivation Neurology, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-2066322-A2 | HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME | Medivation Neurology, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1976518-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | Medivation Neurology, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1937263-A2 | HYDROGENATED PYRIDO-INDOLE COMPOUNDS FOR THE TREATMENT OF HUNTINGTON ' S DISEASE | MEDIVATION, INC. (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008051599-A2 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING I. A. DIMEBON AND DOLEPEZIL | MEDIVATION NEUROLOGY, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008036400-A2 | HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME | MEDIVATION NEUROLOGY, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036410-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | MEDIVATION NEUROLOGY, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| US-20070225316-A1 | Methods and compositions for treating schizophrenia | MEDIVATION, INC. | 2007-09-27 | — | — | US | disclosed |
| WO-2007087425-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | MEDIVATION NEUROLOGY,INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070117835-A1 | Methods and compositions for treating Huntington's disease | MEDIVATION NEUROLOGY, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20070117834-A1 | Methods and compositions for treating Huntington's disease | MEDIVATION NEUROLOGY, INC. | 2007-05-24 | — | — | US | disclosed |
| WO-2007041697-A2 | HYDROGENATED PYRIDO-INDOLE COMPOUNDS FOR THE TREATMENT OF HUNTINGTON ' S DISEASE | MEDIVATION, INC. (GB) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178277-A1 | METHODS AND COMPOSITIONS FOR STIMULATING CELLS | BAD, NFATC1, HDGF | SIGMAR1 3601/4885ACHE 1950/4885APAF1 59/4885 |
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | PSEN2, APP, PSEN1 | SIGMAR1 3799/4885ACHE 12/4885APAF1 3741/4885 |
| US-20070225316-A1 | Methods and compositions for treating schizophrenia | SLC6A3, DBH, GRIN3B | SIGMAR1 1858/4885ACHE 393/4885APAF1 4745/4885 |
| US-20070117835-A1 | Methods and compositions for treating Huntington's disease | HTT, HYPK, HTR6 | SIGMAR1 4376/4885ACHE 171/4885APAF1 4198/4885 |
| US-20100152225-A1 | HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME | HPD, KYNU, IDO1 | SIGMAR1 2584/4885ACHE 1153/4885APAF1 3973/4885 |
| US-20100099700-A1 | HYDROGENATED PYRIDO (4,3-B) INDOLES FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | HTT, NLN, SMN1; SMN2 | SIGMAR1 3754/4885ACHE 164/4885APAF1 1756/4885 |
| US-20110269777-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA USING ANTIPSYCHOTIC COMBINATION THERAPY | SLC6A3, DBH, HTR3B | SIGMAR1 972/4885ACHE 641/4885APAF1 4561/4885 |
| US-20070117834-A1 | Methods and compositions for treating Huntington's disease | HTT, HYPK, HTR6 | SIGMAR1 4376/4885ACHE 171/4885APAF1 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.